Chemotherapy for advanced non-small cell lung cancer

被引：16
作者：
Herbst, RS
Dang, NH
Skarin, AT
机构：
[1] Dana Farber Cancer Institute, Department of Medical Oncology, Boston, MA 02115
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 1997年 / 11卷 / 03期
关键词：
D O I：
10.1016/S0889-8588(05)70445-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Lung cancer is the most lethal cancer in both men and women. Given that chemotherapy for advanced disease is marginally beneficial and noncurative, its use must be governed judiciously, with each decision being evaluated individually for each patient. Chemotherapy for lung cancer has progressed over the past decade, and with the advent of new agents, its future looks promising.
引用
收藏
页码：473 / &
页数：46
相关论文
共 215 条
[1]   EFFICACY AND SAFETY PROFILE OF GEMCITABINE IN NON-SMALL-CELL LUNG-CANCER - A PHASE-II STUDY [J].
ABRATT, RP ;
BEZWODA, WR ;
FALKSON, G ;
GOEDHALS, L ;
HACKING, D ;
RUGG, TA .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (08) :1535-1540
[2]   Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-small-cell lung cancer [J].
Abratt, RP ;
Bezwoda, WR ;
Goedhals, L ;
Hacking, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :744-749
[3]  
Akerley W, 1996, SEMIN ONCOL, V23, P14
[4]   SURVIVAL DETERMINANTS IN EXTENSIVE-STAGE NON-SMALL-CELL LUNG-CANCER - THE SOUTHWEST-ONCOLOGY-GROUP EXPERIENCE [J].
ALBAIN, KS ;
CROWLEY, JJ ;
LEBLANC, M ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (09) :1618-1626
[5]   SINGLE-AGENT ACTIVITY OF WEEKLY GEMCITABINE IN ADVANCED NON-SMALL-CELL LUNG-CANCER - A PHASE-II STUDY [J].
ANDERSON, H ;
LUND, B ;
BACH, F ;
THATCHER, N ;
WALLING, J ;
HANSEN, HH .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (09) :1821-1826
[6]  
ANDERSON H, 1994, P AN M AM SOC CLIN, V13, P367
[7]  
[Anonymous], 1995, BMJ
[8]  
ANTON A, 1996, P AN M AM SOC CLIN, V15, P380
[9]   PACLITAXEL - WHAT SCHEDULE - WHAT DOSE [J].
ARBUCK, SG .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (02) :233-236
[10]  
ARDIZZONI A, 1987, CANCER TREAT REP, V71, P1311
12345678910